Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Delta-like ligand 4" patented technology

Delta-like 4 is a protein that in humans is encoded by the DLL4 gene. This gene is a homolog of the Drosophila delta gene. The delta gene family encodes Notch ligands that are characterized by a DSL domain, EGF repeats, and a transmembrane domain.

Therapeutic methods for treating vascular eye disorders with DII4 antagonists

InactiveUS20080181893A1Inhibition of developmentEnhanced regrowthSenses disorderPeptide/protein ingredientsDiabetic retinopathyIschemic retinopathy
A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (Dll4) activity to a subject in need thereof. In one embodiment, the agent is an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor. The method of the invention is useful for treating eye disorders such as ischemic retinopathy, diabetic retinopathy, age related macular degeneration, corneal neovascularization, neovascular glaucoma, or retinopathy of prematurity. The method is also useful or treating ischemic or vascular disorders such as ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension.
Owner:REGENERON PHARM INC

Methods of treating autoimmune diseases with dll4 antagonists

The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory T cell (Treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of DII4 antagonists that block DII4-Notch signal pathways, thereby increasing the number of Treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (MS), diabetes, and the like. Suitable DII4 antagonists for the invention include antibodies or antibody fragments that specifically bind DII4 and block DII4-Notch interactions, the extracellular domain of DII4, and the like. The invention also provides methods of preventing an occurrence or recurrence of such diseases or disorders in a subject predisposed or susceptible to developing such diseases or disorders. Furthermore, the methods of the invention are useful in preventing or treating organ transplant rejections or graft-versus-host disease.
Owner:REGENERON PHARM INC

Methods of treating diseases with dll4 antagonists

The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit protective effects on pancreatic islets, lower blood glucose levels, and block the production of auto-antibodies, including those against insulin and glutamic acid decarboxylase 65 (GAD65), via the expansion of regulatory T cells (Tregs). Thus, the present invention further provides methods of lowering the levels of blood glucose, and / or reducing or blocking the production of auto-antibodies, by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like.
Owner:REGENERON PHARM INC

Compositions and methods for diagnosing and treating cancer

An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.
Owner:ONCOMED PHARMA

Methods for Treating Melanoma

Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described.
Owner:MEREO BIOPHARMA 5 INC

Anti-human DLL4 and VEGF bispecific antibody and preparation and application thereof

The invention belongs to the field of antibodies. A bispecific antibody targeting to both VEGF and DLL4 is characterized in that the antibody comprises four chains, namely, an amino acid sequence shown by SEQ ID NO: 1, an amino acid sequence shown by SEQ ID NO: 2, an amino acid sequence shown by SEQ ID NO: 3 and an amino acid sequence shown by SEQ ID NO: 4 in sequence. The dual-targeted VEGF and DLL4 bispecific antibody HB-32 is constructed for the first time, and the antibody can be bound with the antigens VEGF and DLL4 respectively and has good antitumor activity.
Owner:CHINA PHARM UNIV

Novel dual-targeted protein specifically binding to DLL4 AND VEGf, and use thereof

ActiveCN105518028AImprove bindingExcellent strength and anticancer effectNervous disorderSkeletal disorderVascular endotheliumBiology
The present invention relates to a dual-targeted protein comprising: a novel protein specifically binding to delta like ligand 4 (DLL4); and an antibody specifically binding to a vascular endothelial cell growth factor (VEGF).
Owner:ABL BIO INC

Application of DLL4 cytokine in preparation of medicine for treating fulminant hepatic failure

The present invention discloses application of DLL4 cytokine in preparation of a medicine for treating fulminant hepatic failure, the medicine includes a DLL4 cytokine pharmaceutically acceptable excipient, an antioxidant and a carrier, the form of medicine can be an injection liquid or frozen dry powder or a suspension, the application temperature of the medicine including the DLL4 cytokine is 15 DEG C-30 DEG C, and the humidity is 45%-75%. Studies on the aspects of biochemical indexes, immunohistochemistry, gene expression level, proteomics and the like show that the DLL4 cytokine can be used in preparation of the medicine for effectively treating fulminant hepatic failure, and different dosages and forms of medicines can be produced by compounding the DLL4 cytokine with different solvents and stabilizers.
Owner:ZHEJIANG UNIV

Anti-human DLL4 monoclonal antibody 3F9

The invention discloses an anti-human DLL4 monoclonal antibody 3F9 which is obtained through secretion of a hybridoma cell strain preserved in CGMCC (China General Microbiological Culture Collection Center) at yard 3, No. 1 Beichen west road, Chaoyang District, Beijing City on June 7, 2017 with the preservation number of CGMCC No.14283. The anti-human DLL4 monoclonal antibody 3F9 is named as hybridoma cell strain 3F9 for secreting the anti-human DLL4 monoclonal antibody. The hybridoma cell strain has the classification and name of hybridoma cell strain 3F9 for secreting the anti-human DLL4 monoclonal antibody. The capability of DLL4+DC for inducing Na-ve T cells to differentiate in the Th1 direction cannot be blocked through binding of the monoclonal antibody 3F9 and DC as compared with commercialized MHD4-46.
Owner:SOOCHOW UNIV AFFILIATED CHILDRENS HOSPITAL

Preparation method of anti-human DLL4 monoclonal antibody 3F9

The invention discloses a preparation method of an anti-human DLL4 monoclonal antibody 3F9 which is obtained through secretion of a hybridoma cell strain preserved in CGMCC (China General Microbiological Culture Collection Center) at yard 3, No. 1 Beichen west road, Chaoyang District, Beijing City on June 7, 2017 with the preservation number of CGMCC No.14283. The anti-human DLL4 monoclonal antibody 3F9 is named as hybridoma cell strain 3F9 for secreting the anti-human DLL4 monoclonal antibody. The hybridoma cell strain has the classification and name of hybridoma cell strain 3F9 for secretingthe anti-human DLL4 monoclonal antibody. The capability of DLL4+DC for inducing Na-ve T cells to differentiate in the Th1 direction cannot be blocked through binding of the monoclonal antibody 3F9 and DC as compared with commercialized MHD4-46.
Owner:SOOCHOW UNIV AFFILIATED CHILDRENS HOSPITAL

Compositions and methods for diagnosing and treating cancer

An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.
Owner:ONCOMED PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products